Supriya Lifescience Sales & Marketing GM Sreekant Sreedharan Granted Bail in NDPS Act Case
New Delhi: Supriya Lifescience Limited's General Manager - Sales & Marketing, Sreekant Sreedharan, has been granted bail by the Sessions Court in connection with judicial proceedings under the Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985.
The company disclosed that the Sessions Court had passed an order granting bail to Sreedharan, subject to the conditions specified in the court's order. The company stated that it had received the court order on November 2, 2026, in continuation of its earlier intimations concerning the judicial proceedings.
The latest regulatory disclosure does not provide further details regarding the allegations, the specific conditions imposed by the court or the circumstances surrounding the case.
Supriya Lifescience clarified in its filing that the court's order would have no material impact on the company's operations. It also stated that it would continue to keep the stock exchanges and stakeholders informed about any further material developments in the matter.
Established in 1987 and headquartered in Mumbai, Supriya Lifescience Limited is a pharmaceutical company engaged in the development and manufacturing of active pharmaceutical ingredients (APIs) and finished pharmaceutical formulations. Its product portfolio spans several therapeutic segments, including antihistamines, anti-allergics, vitamins, anaesthetics and anti-asthmatics.
The company has an international presence, serving customers across global markets through its manufacturing and export operations.
